Mei Wu

Mei Wu is a Principal Medical Science Director specializing in Lymphoma within US Medical Affairs at Genentech, where responsibilities include leading the Follicular Lymphoma Disease Area and overseeing the medical launch of Mosunetuzumab since December 2018. Prior to this role, Mei served as Senior Medical Science Director in Hematology at Pharmacyclics, an AbbVie Company, and held various positions focused on education and scientific communications in hematology at Genentech. Early career experience includes roles as a Pharmacy Practice Resident at Kaiser Permanente and internships with ProPharma Pharmaceutical Consultants, Inc., and the FDA's Center for Drug Evaluation and Research. Mei Wu holds a Bachelor of Arts in Molecular and Cell Biology with a minor in Nutritional Science from the University of California, Berkeley, and a Doctor of Pharmacy degree from the University of Southern California.